An Open-label, Phase 1b/2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, and Ofatumumab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Prolymphocytic Leukemia

Trial Profile

An Open-label, Phase 1b/2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, and Ofatumumab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Prolymphocytic Leukemia

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Ofatumumab
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PCYC-1109-CA
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 08 Dec 2015 Results (pooled analysis of PCYC-1102, PCYC-1112 and PCYC-1109) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (n = 398).
    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 21 Jun 2013 Planned End Date changed from 1 Apr 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top